Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...
UK-based biotechnology company Engitix Ltd. has raised a further $25 million from billionaire Michael Platt to help develop its therapies for cancer and fibrosis.
UCSF scientists engineered old fibroblast cells to turn their genes on and off in the same way as young fibroblasts. The old ...
Researchers at the University of California, Los Angeles (UCLA), in collaboration with pathologists from Hadassah Hebrew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback